The Lobular Breast Cancer Alliance (LBCA) is a patient-driven advocacy network working with a scientific advisory board of breast cancer researchers and clinicians.

Our goal is to promote research that advances prevention, diagnosis, treatment and follow-up care for patients with lobular breast cancer (ILC).

Please join us!

Go to www.lobularbreastcancer.org to learn more, sign up and donate.

Invasive Lobular Breast Cancer (ILC)
a distinct type of breast cancer

- ILC is the second most common histological subtype of breast cancer with 39,000 patients diagnosed each year and approximately 450,000 patients living with the disease in the US.
- ILC is a biologically distinct breast cancer with its own unique subtypes and variants, different clinical presentation and a tendency to metastasize to unique locations. A better understanding of ILC's unique biology and behaviors could open doors to effective targeted therapies.
- Lobular breast cancer is harder to detect in screening, advanced imaging and self-exams leading to later staging at diagnosis.
- ILC may respond differently to standard of care chemotherapy and endocrine therapies, requiring more clinical trials to refine treatments for patients.
- Lobular breast tumors frequently recur many years after initial diagnosis. While ILC is often associated with good initial prognosis, recent analysis suggests that longterm outcomes may be worse.

More Research NEEDED